Key facts
- This page summarizes George A. Eldridge's Form 4 filing for Aerovate Therapeutics, Inc. (JBIO).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Dec 2022, 18:00.
George A. Eldridge - 30 Nov 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)
- Reporting relationship
- Officer Title: Chief Financial Officer and Treasurer
- Issuer ticker
- JBIO
- Reported as of
- 30 Nov 2022
- Net transaction value
- -$1,438
- SEC form
- 4
- Accepted by SEC
- 02 Dec 2022, 18:00:11 UTC
- Prior SEC filing
- 28 Nov 2022
- Next SEC filing
- 09 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ George A. Eldridge
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
George A. Eldridge filed Form 4 for Aerovate Therapeutics, Inc. (JBIO) on 02 Dec 2022.
Change
- Previous filing in this sequence was filed on 28 Nov 2022.
- Current net transaction value: -$1,438.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVTE
transaction
Common Stock
Options Exercise
- Transaction value
- $182
- Shares
- +85
- Change %
- +4.3%
- Price
- $2.14*
- Shares after
- 2,045
- Date
- 30 Nov 2022
- Ownership
- Direct
- Footnotes
- F1
AVTE
transaction
Common Stock
Sale
- Transaction value
- $1,620
- Shares
- -85
- Change %
- -4.2%
- Price
- $19.06
- Shares after
- 1,960
- Date
- 30 Nov 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVTE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -85
- Change %
- -0.09%
- Price
- $0.000000
- Shares after
- 96,293
- Date
- 30 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 85
- Exercise price
- $2.14
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.
Footnote F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.17, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F3
A total of 98,676 shares subject to an employee stock option were granted on April 1, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.
SEC remarks
Officer Title: Chief Financial Officer and Treasurer